Navigation Links
Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
Date:6/10/2008

CHARLOTTESVILLE, Va., June 10 /PRNewswire/ -- Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing new drugs for the treatment of life-threatening unmet medical needs, today announced the addition of Mark T. Giles to its Board of Directors.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080610/NETU101 )

Mr. Giles is the Chairman of the Board of Virginia National Bank in Charlottesville, Virginia. He also is the managing member of Panda Holdings, LLC, which engages in the investment and management of private capital. In addition to VNB and Diffusion Pharmaceuticals LLC, Mr. Giles is a director of GreenVolts, Inc. and Avir Sensors, LLC.

From January 1998 to June 2007, Mr. Giles served as the founding President and CEO of Virginia National Bank and from January 1995 through 1997, he served as President of Sterling Bank and its parent company, Sterling Bancshares, Inc., a publicly-traded Houston, Texas financial institution. Prior to joining Sterling, he had been President of Charter National Bank- Houston and its parent company, Charter Bancshares, Inc., a publicly traded Houston financial institution he had joined in 1986 as Chief Financial Officer. Until 1986, he had practiced law with the banking group of the Houston law firm Bracewell & Guiliani, LLP. In Charlottesville, Mr. Giles chairs the boards of Computers4Kids and the Thomas Jefferson Area United Way. He also is a director of Martha Jefferson Hospital.

In 1977, Mr. Giles received a BS degree in Finance from the McIntire School of Commerce at the University of Virginia and was recipient of the faculty's outstanding finance major award. He received a J.D. degree from the University of Virginia School of Law in 1980.

"We are fortunate that Mr. Giles has decided to join Diffusion Pharmaceuticals' Board of Directors," said David G. Kalergis, CEO. "His extensive experience further strengthens our business and financial leadership capabilities."

About Diffusion Pharmaceuticals LLC

Diffusion Pharmaceuticals LLC is a clinical-stage drug-development company commercializing a family of first-in-class drug candidates to treat serious or life-threatening medical conditions. These proprietary small molecules use a novel method of action to enhance oxygen diffusion to oxygen deprived (hypoxic) tissue. Potential clinical applications include cancer, critical care uses such as trauma, hemorrhage, stroke and heart attack, as well as chronic conditions such as peripheral arterial and vascular disease, cardiovascular disease, and respiratory disorders. Enhanced diffusion of oxygen into hypoxic tissue has an important application in oncology by improving the efficacy of radiation therapy in cancerous tumors. A Phase 1 study for its lead molecule, trans sodium crocetinate (TSC), in healthy subjects was successfully completed in 2007. The company is now initiating proof-of-concept and dose-finding studies in cancer patients undergoing radiation therapy and in peripheral arterial disease patients suffering from intermittent claudication. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia. For more information, visit http://www.diffusionpharma.com.


'/>"/>
SOURCE Diffusion Pharmaceuticals LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled Bipolar Trans Carotenoid Salts and Their Uses, for Its Family of First-In-Class Molecules
2. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
3. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
4. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
5. Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter
6. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
7. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
8. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
9. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
10. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
11. Onyx Pharmaceuticals to Present at Goldman Sachs 29th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):